Last Updated: September 24, 2026

Details for Patent: 11,124,526

Name: Drug Patent Intelligence for US Patent 11124526
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,124,526 protect, and when does it expire?

Patent 11,124,526 protects EXBLIFEP and is included in one NDA.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 11,124,526

Title:	Crystalline beta-lactamase inhibitor
Abstract:	A crystalline compound of formula (I):The compound of formula (I) is a β-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.
Inventor(s):	Alessandro Lamonica, Marco Forzatti, Stefano Biondi
Assignee:	Allecra Therapeutics SAS
Application Number:	US16/177,406
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 11,124,526

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Orchid Pharma	EXBLIFEP	cefepime hydrochloride; enmetazobactam	POWDER;INTRAVENOUS	216165-001	Feb 22, 2024		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,124,526

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014345507	⤷ Start Trial
Canada	2929199	⤷ Start Trial
Chile	2016001097	⤷ Start Trial
China	105873935	⤷ Start Trial
Eurasian Patent Organization	031348	⤷ Start Trial
Eurasian Patent Organization	201690963	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.